With an investment of 15 million euros in the Flemish-Dutch partnership RegMed XB, the Flemish government is giving regenerative medicine a boost. The funding, spread over a five-year period, will be used among other things to develop new regenerative therapies targeting chronic diseases, including osteoarthritis and eye diseases.
Why you need to know this:
Regenerative medicine focuses on the pursuit of a healthy and vital old age by repairing, replacing or restoring damaged cells, tissues and organ functions as a result of disease or injury. New treatment methods based on this concept contribute to effectively managing healthcare costs.
Within RegMed XB, universities, research institutes, companies, health funds and government work together in large-scale joint projects with a specific goal. Forces are pooled to bring new tissues to the market that enable the repair of diseased organs (such as the heart, kidneys and pancreas).
Over the past few years, RegMed XB has taken a number of important steps. One example is the developments of stem cell derived insulin-producing cells in a protective pouch for the treatment of type I diabetes. Furthermore, steps were also taken in research into the development of biological functional implants for the treatment of failing organs such as joints and kidneys. Infrastructure was also developed for the production of these replacement structures that reinforces this research and development across borders. All this in cooperation between Flemish and Dutch universities and knowledge institutions.
New therapies
The investment will boost, among other things, new therapies for osteoarthritis and eye diseases, which will be developed by a consortium of knowledge institutions and companies from Flanders and the Netherlands. In addition, the funding will be used to strengthen the organisation that will support this Flemish-Dutch network.
Related Posts
